Ozempic 1mg Semaglutide: the Dose, the Licence, and What UK Patients Need to Know

What the clinical evidence says about semaglutide 1mg — and what it doesn't say

The pivotal SUSTAIN trial programme, which underpins Ozempic's MHRA authorisation, tested semaglutide at 0.5mg and 1mg in adults with type 2 diabetes. At 1mg, participants achieved meaningful reductions in HbA1c and also lost weight as a secondary outcome, typically around 4–6kg over the trial periods. That weight loss was a side effect of glycaemic control, not a primary endpoint. The trials enrolled people with diabetes; the results cannot simply be read across to adults without the condition.

The reason this distinction matters in practice: the NHS medicines information for semaglutide is explicit that Ozempic is for type 2 diabetes and Wegovy is for weight management, same active ingredient, different licensed indications, different licensed doses, different clinical populations. The MHRA reinforces this on GOV.UK, stating that GLP-1 receptor agonist medicines are not assessed for quick or cosmetic weight loss. Citing the diabetes trial data to justify prescribing 1mg semaglutide for weight loss is therefore not how a responsible UK prescriber approaches this.

Separately, for people who do have type 2 diabetes and are also carrying excess weight, a diabetes prescriber may find 1mg Ozempic clinically appropriate, but that decision belongs with their GP or diabetes team, not an online weight-loss service.

How Ozempic's 1mg dose fits into the semaglutide dose schedule

Ozempic is injected once weekly via a pre-filled pen. The prescribing schedule starts at 0.25mg for four weeks to help the body adjust, steps to 0.5mg, then to 1mg at week twelve if tolerated and clinically indicated. A 2mg dose is also available for patients whose diabetes management requires it. Each step is a prescriber decision, not a patient one. You can read more about how the semaglutide dose schedule works for Ozempic, the titration logic, the pen formats, and why the steps are timed the way they are.

The 1mg dose became familiar to many people because Ozempic 1mg pens were among those cited during the semaglutide supply shortages of 2023–2025, when widespread off-label prescribing for weight loss put pressure on a supply chain built around diabetes patients. The MHRA and NHS England responded with guidance urging that stock be prioritised for people with type 2 diabetes. That context is worth remembering: a medicine can be well-known without being the right tool for a given job.

For anyone curious about where semaglutide doses sit across the full range of products (from the 0.25mg Ozempic starter through to the 25mg Wegovy tablet) the 1mg semaglutide page sets out those distinctions in one place.

The weight-loss medicines actually licensed for this purpose in the UK

Two medicines currently hold MHRA authorisation for weight management in UK adults: Wegovy (semaglutide) and Mounjaro (tirzepatide). Wegovy is semaglutide in the same way Ozempic is semaglutide, but the Wegovy licence, its dose range, and the clinical trials behind it were built around weight management specifically. The STEP 1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 15% over 68 weeks at the 2.4mg maintenance dose, in adults without diabetes. More recently, a 7.2mg Wegovy dose was approved by the MHRA (including, from April 2026, a dedicated single-dose pen) with trial data reporting average losses approaching 20.7% over 72 weeks.

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist: it activates two appetite-regulating pathways rather than one. NICE recommended it in December 2024 (TA1026) for eligible adults, and head-to-head evidence from the SURMOUNT-5 trial, published in the NEJM in 2025, found it produced greater average weight reduction than semaglutide 2.4mg. You can compare the two in more depth on the Wegovy doses overview, or explore the broader weight-loss treatment options on the site.

There is also now an oral option: oral semaglutide in tablet form (Wegovy tablets) was approved by the MHRA on 11 June 2026, the first oral GLP-1 licensed in the UK for weight management. It uses semaglutide at a 25mg maintenance dose taken first thing in the morning, on an empty stomach, with a small amount of plain water. No needles, no refrigeration. Worth knowing if injections have been a barrier.

If you are wondering how the Ozempic and Wegovy dose scales map onto each other, the answer is that they are not directly interchangeable, the licensed dose ceiling for weight management (2.4mg weekly, or 7.2mg with the newer pen) sits well above Ozempic's approved diabetes doses, and the clinical oversight frameworks differ too.

Getting started with a licensed weight-loss treatment through a regulated UK pharmacy

Wegovy and Mounjaro are prescription-only medicines. The only legal route to either in the UK is a prescription following a clinical assessment, a prescriber reviews your health history, current medicines, BMI and any relevant conditions before deciding whether treatment is appropriate and, if so, at what starting dose. There is no shortcut that keeps you safe.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, the same day. Orders placed before midday on a working day are dispatched the same day once approved, arriving free the next working day via DPD in plain, unbranded packaging. One transparent price covers consultation, prescription and delivery; there are no subscriptions or auto-renewals. Our about us page sets out how the service is structured and regulated.

You can verify our pharmacy on the GPhC register at the GPhC register (registration number 9012878), verifying any online pharmacy before you order is a sensible first step regardless of which service you use. If you have questions before starting, our FAQs cover the most common ones, or you can get in touch directly.

If you are ready to find out whether Wegovy or Mounjaro is appropriate for you, start your free consultation and a prescriber will review your answers the same day.